We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesCuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
1.73 USD 0.01 ( 0.58%)
Last update at 2026-11-12T14:51:00Z
VOLUME
836
Market Cap
7.86M

Momentum Score

…

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.67
Low
1.73
High
52 Week Price Range
1.76
Low
12.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR) has limited publicly available disclosures about its business and assets, so its specific operations are not well documented. Long-term growth drivers and investor appeal depend on the company's underlying asset base, execution of any development plans and market exposures; investors should monitor regulatory filings and operational updates to assess prospects.

Major risks include scarce transparency, execution and financing risk for undeveloped assets, and exposure to commodity, regulatory or jurisdictional risks related to any underlying operations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.72
Dividend Yield
-
Revenue TTM
0.05M
Revenue Per Share
0.02
Gross Profit TTM
-0.00M
Debt / Equity
0.10
ROE
-1569.06%
Net Debt
-2.63M
ROCE
-85.27%
Diluted EPS TTM
-1.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -4.67M -1.51M -1.09M -1.09M -0.52M
Net income -4.67M -1.56M -1.12M -1.09M -0.52M
Selling general administrative 4.39M 1.26M 0.83M 0.79M 0.25M
Selling and marketing expenses 0.01M 0.01M 0.01M 0.04M 0.00M
Gross profit -0.00M -0.00M 0.04M 0.02M 0.02M
Reconciled depreciation 0.04M 0.04M 0.04M 0.03M 0.03M
Ebit -4.60M -1.47M -1.03M -1.09M -0.52M
Ebitda -4.56M -1.43M -0.99M -1.06M -0.49M
Depreciation and amortization 0.04M 0.04M 0.04M 0.03M 0.03M
Operating income -4.57M -1.65M -1.07M -1.18M -0.55M
Other operating expenses 4.62M 1.69M 1.17M 1.23M 0.61M
Interest expense 0.01M 0.04M 0.06M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.03M - - - -
Net interest income 0.01M -0.04M -0.06M -0.00M -0.00M
Income tax expense - 0.05M 0.03M 0.01M -
Total revenue 0.05M 0.05M 0.10M 0.06M 0.06M
Total operating expenses 4.57M 1.64M 1.10M 1.20M 0.58M
Cost of revenue 0.05M 0.05M 0.06M 0.04M 0.04M
Total other income expense net -0.11M 0.14M -0.02M 0.09M 0.03M
Net income from continuing ops -4.67M -1.56M -1.12M -1.09M -0.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8.50M 1.75M 1.59M 1.44M 0.95M
Other current assets 3.96M 1.42M 1.18M 0.26M 0.02M
Total liab 3.45M 6.20M 4.48M 3.21M 1.64M
Total stockholder equity 5.06M -4.46M -2.90M -1.78M -0.68M
Other current liab 2.97M 5.95M 4.36M 3.03M 1.47M
Common stock 0.03M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.03M 0.02M 0.02M 0.02M 0.02M
Retained earnings -9.23M -4.56M -3.00M -1.88M -0.79M
Cash 3.12M 0.12M 0.04M 0.56M 0.77M
Total current liabilities 3.12M 6.04M 4.43M 3.09M 1.51M
Net debt -2.63M 0.14M 0.09M -0.38M -0.60M
Short term debt 0.15M 0.09M 0.06M 0.06M 0.04M
Short long term debt 0.04M 0.06M 0.02M 0.02M 0.02M
Short long term debt total 0.48M 0.25M 0.12M 0.18M 0.17M
Other stockholder equity 13.91M 0.08M 0.08M 0.08M 0.08M
Total current assets 7.33M 1.66M 1.44M 1.27M 0.81M
Long term investments 0.00M 0.00M 0.00M 0.01M 0.00M
Net receivables 0.26M 0.12M 0.21M 0.44M 0.02M
Long term debt 0.13M 0.16M 0.02M 0.04M 0.06M
Inventory 0.00M 0.00M 0.01M 0.01M 0.00M
Accounts payable 0.00M - 0.00M 0.00M 0.00M
Accumulated other comprehensive income 0.35M -0.00M 0.00M -0.00M -
Non currrent assets other 0.78M - - - -
Non current assets total 1.17M 0.09M 0.15M 0.17M 0.14M
Capital lease obligations 0.32M 0.04M 0.08M 0.12M 0.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M -0.07M -0.03M -0.00M
Total cashflows from investing activities -0.06M -0.02M -0.07M -0.03M -0.00M
Net borrowings -0.05M 0.18M -0.02M -0.02M 0.08M
Total cash from financing activities 12.23M 1.34M 1.08M 1.68M 0.99M
Net income -4.67M -1.56M -1.12M -1.09M -0.52M
Change in cash 3.00M 0.08M -0.53M -0.20M 0.77M
Begin period cash flow 0.12M 0.04M 0.56M 0.77M 0.00M
End period cash flow 3.12M 0.12M 0.04M 0.56M 0.77M
Total cash from operating activities -9.13M -1.24M -1.54M -1.85M -0.22M
Issuance of capital stock 17.61M - - - -
Depreciation 0.04M 0.04M 0.04M 0.03M 0.03M
Change to inventory 0.00M 0.00M -0.00M -0.01M 0.00M
Change to account receivables 0.01M 0.02M -0.04M -0.04M -0.02M
Other cashflows from financing activities -5.32M 1.16M 1.10M 1.70M 0.91M
Capital expenditures 0.06M 0.02M 0.07M 0.02M 0.00M
Change in working capital -4.70M 0.23M -0.52M -0.81M 0.27M
Other non cash items 0.20M 0.05M 0.06M 0.02M 0.00M
Free cash flow -9.19M -1.26M -1.61M -1.87M -0.22M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares		 0.01
0.58%		 1.73 - - 157.46 2.17 166.53
ISRG
Intuitive Surgical Inc		 -8.88
1.97%		 440.65 43.30 31.35 12.25 7.35 11.63
ESLOF
EssilorLuxottica Société anonyme		 -2.56
1.26%		 200.18 44.84 27.62 4.07 2.49 3.71
ESLOY
Essilor International SA		 -1.98
1.94%		 99.87 41.68 27.25 3.94 2.45 3.71
BDX
Becton Dickinson and Company		 0.83
0.39%		 215.35 31.62 13.76 2.25 2.04 2.93

Profile*

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.

Blk 1090, Singapore, Singapore, 169201

65 8512 7275

https://www.cuprina.com.sg

10

Name Title Year Born
Mr. Yong Qi Quek CEO & Director 1995
Mr. Tat Jing Chan Chief Financial Officer 1992
Dr. Ronald Sherman Medical & Scientific Director NA
Mr. Tat Jing Chan Chief Financial Officer 1993

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…